Floatz logo

Therapeutic Asset Ratings

3,272 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Vismodegib
Colon Carcinoma
National Cancer Institute (NCI)P2D (15)
Vismodegib
Hematopoietic And Lymphoid Cell Neoplasm
National Cancer Institute (NCI)P2D (15)
Vismodegib
Renal Carcinoma
National Cancer Institute (NCI)P2D (15)
Vismodegib
Uterine Corpus Cancer
National Cancer Institute (NCI)P2D (15)
Vismodegib
Uterine Cancer
National Cancer Institute (NCI)P2D (15)
Egfr/B7H3 Car-T
Neuroendocrine Carcinoma
National Cancer Institute (NCI)P1D (15)
Cbx-12
Colorectal Carcinoma
National Cancer Institute (NCI)P2NR ()
Ceralasertib
Cholangiocarcinoma
National Cancer Institute (NCI)P2NR ()
Pevonedistat
Non-Small Cell Squamous Lung Carcinoma
National Cancer Institute (NCI)P2NR ()
Pevonedistat
Non-Small Cell Lung Carcinoma
National Cancer Institute (NCI)P2NR ()
IL-12 GEMys
Refractory Malignant Neoplasm
National Cancer Institute (NCI)P1NR ()
IL-12 GEMys
Cancer
National Cancer Institute (NCI)P1NR ()
Tolinapant
Her2-Receptor Negative Breast Cancer
National Cancer Institute (NCI)P1NR ()
Triapine
Diffuse Glioma, H3 G34 Mutant
National Cancer Institute (NCI)P1NR ()
Triapine
Diffuse Midline Glioma, H3 K27M-Mutant
National Cancer Institute (NCI)P1NR ()
Triapine
Brain Astrocytoma
National Cancer Institute (NCI)P1NR ()
Turalio
Plexiform Neurofibroma
National Cancer Institute (NCI)P1NR ()
Tolinapant
Fallopian Tube Adenocarcinoma
National Cancer Institute (NCI)P1/2NR ()
Tolinapant
Ovarian Endometrioid Adenocarcinoma
National Cancer Institute (NCI)P1/2NR ()
Tolinapant
Ovarian Adenocarcinoma
National Cancer Institute (NCI)P1/2NR ()
Tolinapant
Ovarian Seromucinous Carcinoma
National Cancer Institute (NCI)P1/2NR ()
Tolinapant
Primary Peritoneal Serous Adenocarcinoma
National Cancer Institute (NCI)P1/2NR ()
Showing 3251 to 3272 of 3,272 assets
PreviousPage 131 of 131Next